Advertisement

Drugs & Aging

, Volume 28, Issue 5, pp 345–367 | Cite as

Effects of Selective Serotonin Reuptake Inhibitors on Platelet Function

Mechanisms, Clinical Outcomes and Implications for Use in Elderly Patients
  • Francisco J. de Abajo
Review Article

Abstract

Among the antidepressants, the selective serotonin reuptake inhibitors (SSRIs) are often preferred to other classes of antidepressants in the treatment of depression in the elderly because of their better safety profile. Most of the known effects of SSRIs, either beneficial or adverse, are linked to their inhibitory action on the serotonin reuptake transporter (5-HTT). This reuptake mechanism is present not only in neurons but also in other cells such as platelets.

Serotoninergic mechanisms seem to play an important role in haemostasis, and their importance in this regard has long been underestimated. Abnormal activation may lead to a pro-thrombotic state, as may occur in patients with major depressive disorder, whilst downregulation, as occurs in patients treated with SSRIs, may have two clinical consequences, both of particular interest in the elderly. On the one hand, there may be an increased risk of bleeding; on the other hand, a reduction in thrombotic risk may be possible. Polymorphism in the promoter region of the gene that transcribes the 5-HTT has been shown to have a relevant impact on its function and, in turn, on the beneficial and adverse effects of SSRIs.

Bleeding has been a concern since the introduction of SSRIs, with multiple case reports published and communicated to the pharmacovigilance systems. The first epidemiological study was published in 1999 and since then, 34 epidemiological studies from different areas, most of them including elderly patients in their study populations, have been published with a variety of results. Broadly, the epidemiological evidence supports a moderately increased risk of bleeding associated with the use of SSRIs, which may be critically dependent on patient susceptibility and the presence of risk factors.

The impairment of primary haemostasis induced by SSRIs may result, as a beneficial counterpart, in a reduction in the thrombotic risk. A small number of clinical trials and an increasing number of epidemiological studies that include elderly patients have been conducted to clarify whether SSRIs reduce the risk of primary and secondary ischaemic disorders. However, the results have been inconclusive with some studies suggesting a preventive effect and others no effect or even an increased risk. Behind such contradictory results may be the role of depression itself as a cardiovascular risk factor and, therefore, a major confounding factor. How to disentangle its effect from that of the antidepressants is the methodological challenge to be overcome in future studies.

In this complex scenario, the elderly seem to be at a crossroads, because they are the group in which both the risks and the benefits can be the greatest. Studies performed to date have provided us with some clues that can help orient clinicians in taking the most appropriate course of action. For instance, as the gastrointestinal bleeding risk appears to increase with age, prudent advice in patients with a previous history of upper-gastrointestinal bleeding or peptic ulcer, and in those who take NSAIDs, oral anticoagulants, antiplatelet drugs or corticosteroids, would be to suggest addition of an acid-suppressing agent to the drug regimen in those elderly patients in whom SSRIs are indicated.

Keywords

Gastrointestinal Bleeding Major Depressive Disorder Platelet Function Escitalopram Oral Anticoagulant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

The author wishes to thank Guillermo de Abajo for the elaboration of the image depicted in figure 1. The present work was supported by research grants from Fondo de Investigaciones Sanitarias (PI040083 and PI071064). The author has declared no conflicts of interest.

Supplementary material

40266_2012_28050345_MOESM1_ESM.pdf (14 kb)
Supplementary material, approximately 14 KB.

References

  1. 1.
    Lynnes JM, Caine ED, King DA, et al. Psychiatric disorders in older primary care patients. J Gen Intern Med 1999; 14: 249–54CrossRefGoogle Scholar
  2. 2.
    Hybels CF, Blazer DG. Epidemiology of late-life mental disorders. Clin Geriatr Med 2003; 19: 663–96PubMedCrossRefGoogle Scholar
  3. 3.
    Unutzer J. Late-life depression. N Engl J Med 2006; 357: 2269–76CrossRefGoogle Scholar
  4. 4.
    Unutzer J, Katon W, Callahan CM, et al. Depression treatment in a sample of 1,801 depressed older adults in primary care. J Am Geriatr Soc 2003; 51: 505–14PubMedCrossRefGoogle Scholar
  5. 5.
    Stone MB, Jones ML. Clinical review: relationship between antidepressant drugs and suicidality in adults [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf [Accessed 2011 Feb 10]
  6. 6.
    Draper B, Berman K. Tolerability of selective serotonin reuptake inhibitors: issues relevant to the elderly. Drugs Aging 2008; 25: 501–19PubMedCrossRefGoogle Scholar
  7. 7.
    Cheeta S, Schifano F, Oyfeso A, et al. Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998–2000. Br J Psychiatry 2004; 184: 41–7PubMedCrossRefGoogle Scholar
  8. 8.
    Harman JS, Edlund MJ, Fortney JC. Trends in antidepressant utilization from 2001 to 2004. Psychiatr Serv 2009; 60: 611–6PubMedCrossRefGoogle Scholar
  9. 9.
    Newman SC, Schopflocher D. Trends in antidepressant prescriptions among the elderly in Alberta during 1997 to 2004. Can J Psychiatry 2008; 53: 704–7PubMedGoogle Scholar
  10. 10.
    Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med 2009; 60: 355–66PubMedCrossRefGoogle Scholar
  11. 11.
    Lingjarde O. Blood platelets as a model system for studying serotonergic dysfunction and effects of antidepressants. Pharmacol Toxicol 1990; 66Suppl. 3: 61–8CrossRefGoogle Scholar
  12. 12.
    Lesch KP, Wolozin BL, Murphy DL, et al. Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem 1993; 60: 2319–22PubMedCrossRefGoogle Scholar
  13. 13.
    Serebruany VL, O’Connor CM, Krishnan RR, et al. Hypothesis: antiplatelet effects of selective serotonin reuptake inhibitors cause clinical benefits on cardiovascular disease and increase risks of bleeding. J Cardiovasc Pharmacol Ther 2005; 10: 163–4PubMedCrossRefGoogle Scholar
  14. 14.
    Skop BP, Brown TM. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics 1996; 37: 12–6PubMedCrossRefGoogle Scholar
  15. 15.
    Gerretsen P, Pollock BG. Pharmacogenetics and the serotonin transporter in late-life depression. Expert Opin Drug Metab Toxicol 2008; 4: 1465–78PubMedCrossRefGoogle Scholar
  16. 16.
    Luddington NS, Madadapu A, Husk M, et al. Clinical implications of genetic variation in the serotonin transporter promoter region: a review. J Clin Psychiatry 2009; 11:93–102Google Scholar
  17. 17.
    Lotrich FE, Pollock BG, Kirshner M, et al. Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients. J Psychiatry Neurosci 2008; 33: 123–30PubMedGoogle Scholar
  18. 18.
    Galan AM, Lopez-Vilchez I, Diaz-Ricart M, et al. Serotonergic mechanisms enhance platelet-mediated thrombogenicity. Thromb Haemost 2009; 102: 511–9PubMedGoogle Scholar
  19. 19.
    Malinin AI, Ong S, Makarov LM, et al. Platelet inhibition beyond conventional antiplatelet agents: expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors. Int J Clin Pract 2006; 60: 993–1002PubMedCrossRefGoogle Scholar
  20. 20.
    Maurer-Spurej E. Serotonin reuptake inhibitors and cardiovascular diseases: a platelet connection. Cell Mol Life Sci 2005; 62: 159–70PubMedCrossRefGoogle Scholar
  21. 21.
    Markovitz JH, Shuster JL, Chitwood WS, et al. Platelet activation in depression and effects of sertraline treatment: an open-label study. Am J Psychiatry 2000; 157: 1006–8PubMedCrossRefGoogle Scholar
  22. 22.
    Musselman DL, Marzec UM, Manatunga A, et al. Platelet reactivity in depressed patients treated with paroxetine: preliminary findings. Arch Gen Psychiatry 2000; 57: 875–82PubMedCrossRefGoogle Scholar
  23. 23.
    Shimbo D, Child J, Davidson K, et al. Exaggerated serotonin-mediated platelet reactivity as a possible link in depression and acute coronary syndromes. Am J Cardiol 2002; 89: 331–3PubMedCrossRefGoogle Scholar
  24. 24.
    Whyte EM, Pollock BG, Wagner WR, et al. Influence of serotonin-transporter-linked promoter region polymorphism on platelet activation in geriatric depression. Am J Psychiatry 2001; 158: 2074–6PubMedCrossRefGoogle Scholar
  25. 25.
    Dale GL. Coated-platelets: an emerging component of the procoagulant response. J Thromb Haemost 2005; 3: 2185–92PubMedCrossRefGoogle Scholar
  26. 26.
    Prodan CI, Joseph PM, Vincent AS, et al. Coated-platelet levels are influenced by smoking, aspirin and selective serotonin reuptake inhibitors. J Thromb Haemost 2007; 5: 2149–51PubMedCrossRefGoogle Scholar
  27. 27.
    Wagner A, Montero D, Martensson B, et al. Effects of fluoxetine treatment of platelet 3H-imipramine binding, 5-HT uptake and 5-HT content in major depressive disorder. J Affect Dis 1990; 20: 101–13CrossRefGoogle Scholar
  28. 28.
    Hergovich N, Aigner M, Eichler HG, et al. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther 2000; 68: 435–42PubMedCrossRefGoogle Scholar
  29. 29.
    Javors MA, Houston JP, Tekell JL, et al. Reduction of platelet serotonin content in depressed patients treated with either paroxetine or desipramine. Int J Neuropsychopharmacol 2000; 3: 229–35PubMedCrossRefGoogle Scholar
  30. 30.
    Martensson B, Wagner A, Beck O, et al. Effects of clomipramine treatment on cerebrospinal fluid monoamine metabolites and platelet 3H-imipramine binding and serotonin uptake and concentration in major depressive disorder. Acta Psychiatr Scand 1991; 83: 125–33PubMedCrossRefGoogle Scholar
  31. 31.
    Pigott TA, L’Hereux F, Rubenstein CS, et al. A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1992; 12: 156–62PubMedGoogle Scholar
  32. 32.
    Mück-Seler D, Jakovjevic M, Deanovic Z. Effect of anti-depressant treatment on platelet 5-HT content and relation to therapeutic outcome in unipolar depressive patients. J Affect Dis 1991; 23: 157–64PubMedCrossRefGoogle Scholar
  33. 33.
    Narayan M, Anderson G, Cellar J, et al. Serotonin transporter-blocking properties of nefazodone assessed by measurement of platelet serotonin. J Clin Psychopharmacol 1998; 18: 67–71PubMedCrossRefGoogle Scholar
  34. 34.
    Tatsumi M, Groshan K, Blakely RD, et al. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997; 340: 249–58PubMedCrossRefGoogle Scholar
  35. 35.
    Berk M, Jacobson BF, Hurly E. Fluoxetine and hemostatic function: a pilot study. J Clin Psychiatry 1995; 56: 14–6PubMedGoogle Scholar
  36. 36.
    Alderman CP, Moritz CK, Ben-Tovim DL. Abnormal platelet aggregation associated with fluoxetine therapy. Ann Pharmacother 1992; 26: 1517–9PubMedGoogle Scholar
  37. 37.
    Halperin D, Reber G. Influence of antidepressants on hemostasis. Dialogues Clin Neurosci 2007; 9: 47–59PubMedGoogle Scholar
  38. 38.
    Abdelmalik N, Ruhé HG, Barwari K, et al. Effect of the selective serotonin reuptake inhibitor paroxetine on platelet function is modified by a SLC6A4 serotonin transporter polymorphism. J Thromb Haemost 2008; 6: 2168–74PubMedCrossRefGoogle Scholar
  39. 39.
    Ruhe HG, Booij J, Weert HC, et al. Evidence why dose-escalation of paroxetine in major depressive disorder is not effective: a 6-week, randomized-controlled trial with assessment of serotonin transporter occupancy. Neuro-psychopharmacology 2009; 34: 999–1010CrossRefGoogle Scholar
  40. 40.
    Hougardy DM, Egberts TC, van der Graaf F, et al. Serotonin transporter polymorphism and bleeding time during SSRI therapy. Br J Clin Pharmacol 2008; 65: 761–6PubMedCrossRefGoogle Scholar
  41. 41.
    Humphries JE, Wheby MS, VandenBerg SR. Fluoxetine and the bleeding time. Arch Pathol Lab Med 1990; 114: 727–8PubMedGoogle Scholar
  42. 42.
    Yaryura-Tobias JA, Kirschen H, Ninan P, et al. Fluoxetine and bleeding in obsessive-compulsive disorder [letter]. Am J Psychiatry 1991; 148:949PubMedGoogle Scholar
  43. 43.
    Ottervanger JP, Stricker BHCH, Huls J, et al. Bleeding attributed to the intake of paroxetine. Am J Psychiatry 1994; 151:781–2PubMedGoogle Scholar
  44. 44.
    Leung M, Shore R. Fluvoxamine-associated bleeding. Can J Psychiatry 1996; 41: 604–5PubMedGoogle Scholar
  45. 45.
    Calhoun JW, Calhoun DD. Prolonged bleeding time in a patient treated with sertraline [letter]. Am J Psychiatry 1996; 153: 443PubMedGoogle Scholar
  46. 46.
    Khon S, Labbate LA. Venlafaxine and ecchymosis [letter]. Can J Psychiatry 1997; 42: 91Google Scholar
  47. 47.
    Balhara Y, Sagar R, Varghese ST. Bleeding gums: duloxetine may be the cause. J Postgrad Med 2007; 53: 44–5PubMedCrossRefGoogle Scholar
  48. 48.
    De Abajo FJ, Montero D, García Rodríguez LA, et al. Antidepressants and risk of upper gastrointestinal bleeding. Pharmacol Toxicol 2006; 98: 304–10Google Scholar
  49. 49.
    De Abajo FJ, García Rodríguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 1999; 319: 1106–9PubMedCrossRefGoogle Scholar
  50. 50.
    Dunn NR, Pearce GL, Shakir SAW. SSRIs are not more likely than other drugs to cause such bleeding. BMJ 2000; 320: 1405–6PubMedCrossRefGoogle Scholar
  51. 51.
    Van Walraven C, Mamdami MM, Wells PS, et al. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ 2001; 323: 1–6CrossRefGoogle Scholar
  52. 52.
    Dalton SO, Johansen C, Mellemkjaer L, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 2003; 165: 59–64CrossRefGoogle Scholar
  53. 53.
    Tata LJ, Fortun PJ, Hubbard RB, et al. Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding? Aliment Pharmacol Ther 2005; 22: 175–81PubMedCrossRefGoogle Scholar
  54. 54.
    Wessinger S, Kaplan M, Choi L, et al. Increased use of selective serotonin reuptake inhibitors in patients admitted with acute gastrointestinal hemorrhage: a multi-centre retrospective analysis. Aliment Pharmacol Ther 2006; 23: 937–44PubMedCrossRefGoogle Scholar
  55. 55.
    Opatrny L, Delaney JA, Suissa S. Gastrointestinal bleed risk with the use of selective serotonin receptor antagonists: a new look. Abstracts of the 23rd ICPE. Pharmacoepidemiol Drug Saf 2007; 16: S1–274Google Scholar
  56. 56.
    Helin-Salmivaara A, Huttunen T, Grönroos JM, et al. Risk of serious upper gastrointestinal events with concurrent use of NSAIDs and SSRIs: a case-control study in the general population. Eur J Clin Pharmacol 2007; 63: 403–8PubMedCrossRefGoogle Scholar
  57. 57.
    Lewis JD, Strom BL, Localio AR, et al. Moderate to high affinity serotonin reuptake inhibitors increase the risk of upper gastrointestinal toxicity. Pharmacoepidemiol Drug Saf 2008; 17: 328–35PubMedCrossRefGoogle Scholar
  58. 58.
    Vidal X, Ibañez L, Vendrell L, et al., on behalf of the Spanish-Italian Collaborative Group for the Epidemiology of Gastrointestinal Bleeding. Risk of upper gastrointestinal bleeding and the degree of serotonin reuptake inhibition by antidepressants: a case-control study. Drug Saf 2008; 31: 159–68PubMedCrossRefGoogle Scholar
  59. 59.
    De Abajo FJ, García-Rodríguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry 2008; 65: 795–803PubMedCrossRefGoogle Scholar
  60. 60.
    Barbui C, Andretta M, De Vitis G, et al. Antidepressant drug prescription and risk of abnormal bleeding: a case-control study. J Clin Psychopharmacol 2009; 29: 33–8PubMedCrossRefGoogle Scholar
  61. 61.
    Targownik LE, Bolton JM, Metge CJ, et al. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol 2009; 104: 1475–82PubMedCrossRefGoogle Scholar
  62. 62.
    Dall M, Schaffalitzky de Muckadell OB, Lassen AT, et al. An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding. Clin Gastroenterol Hepatol 2009; 7: 1314–21PubMedCrossRefGoogle Scholar
  63. 63.
    Verdel BM, Souverein PC, Meenks SD, et al. Use of serotonergic drugs and the risk of bleeding. Clin Pharmacol Ther 2011; 89: 89–96PubMedCrossRefGoogle Scholar
  64. 64.
    Tanaka A, Takahira Y, Izumi N, et al. Aggravation by selective serotonin re-uptake inhibitors (SSRIs) of antral lesions induced by indomethacin in rats: effects of anti-secretory and mucosal protective drugs [abstract]. Gastroenterology 2005: M2063Google Scholar
  65. 65.
    Yamaguchi T, Hidaka N, Suemaru K, et al. The coadministration of paroxetine and low-dose aspirin synergistically enhances gastric ulcerogenic risk in rats. Biol Pharm Bull 2008; 31: 1371–5PubMedCrossRefGoogle Scholar
  66. 66.
    Yamamoto T, Abe K, Hattori K, et al. High prevalence of gastroduodenal mucosa injury in patients taking selective serotonin reuptake inhibitors [letter]. Digestive Endoscopy 2010; 22: 77PubMedCrossRefGoogle Scholar
  67. 67.
    Dall M, Schaffalitzky de Muckadell OB, Lassen AT, et al. There is an association between selective serotonin reuptake inhibitor use and uncomplicated peptic ulcers: a population-based case-control study. Aliment Pharmacol Ther 2010; 32: 1383–91PubMedCrossRefGoogle Scholar
  68. 68.
    Gutthann SP, García Rodríguez LA, Raiford DS. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997; 8: 18–24PubMedCrossRefGoogle Scholar
  69. 69.
    Hernández-Díaz S, García Rodríguez LA. Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies. J Clin Epidemiol 2002; 55: 157–63PubMedCrossRefGoogle Scholar
  70. 70.
    Movig KLL, Janssen MWHE, Malefijt JW, et al. Relationship of serotoninergic antidepressants and need for blood transfusion in orthopedic surgical patients. Arch Intern Med 2003; 163: 2354–8PubMedCrossRefGoogle Scholar
  71. 71.
    Andreasen JJ, Riis A, Hjortdal VE, et al. Effect of selective serotonin reuptake inhibitors on requirements for allogeneic red blood transfusion following coronary artery bypass surgery. Am J Cardiovasc Drugs 2006; 6: 243–50PubMedCrossRefGoogle Scholar
  72. 72.
    Salkeld E, Ferris LE, Juurlink DN. The risk of postpartum hemorrhage with selective serotonin reuptake inhibitors and other antidepressants. J Clin Psychopharmacol 2008; 28: 230–4PubMedCrossRefGoogle Scholar
  73. 73.
    Kim DH, Daskalakis C, Whellan DJ, et al. Safety of selective serotonin reuptake inhibitor in adults undergoing coronary artery bypass grafting. Am J Cardiol 2009; 103: 1391–5PubMedCrossRefGoogle Scholar
  74. 74.
    Xiong GL, Jiang W, Clare RM, et al. Safety of selective serotonin reuptake inhibitor use prior to coronary artery bypass grafting. Clin Cardiol 2010; 33: E94–8PubMedCrossRefGoogle Scholar
  75. 75.
    Gärtner R, Cronin-Fenton D, Hundborg HH, et al. Use of selective serotonin reuptake inhibitors and risk of re-operation due to post-surgical bleeding in breast cancer patients: a Danish population-based cohort study. BMC Surg 2010; 10: 3PubMedCrossRefGoogle Scholar
  76. 76.
    Van Haelst IM, Egberts TC, Doodeman HJ, et al. Use of serotonergic antidepressants and bleeding risk in orthopedic patients. Anesthesiology 2010; 112: 631–6PubMedCrossRefGoogle Scholar
  77. 77.
    Ware JA, Coller BS. Platelet morphology, biochemistry, and function. In: Beutler E, Lichtman MA, Coller BS, et al., editors. William’s hematology. 5th ed. New York: McGraw-Hill, 1995: 1161–93Google Scholar
  78. 78.
    De Abajo FJ, Jick H, Derby L, et al. Intracranial haemorrhage and use of selective serotonin reuptake inhibitors. Br J Clin Pharmacol 2000; 50: 43–7PubMedCrossRefGoogle Scholar
  79. 79.
    Bak S, Tsiropoulos I, Kjaersgaad JO, et al. Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study. Stroke 2002; 33: 1465–73PubMedCrossRefGoogle Scholar
  80. 80.
    Kharofa J, Sekar P, Haverbusch M, et al. Selective serotonin reuptake inhibitors and risk of hemorrhagic stroke. Stroke 2007; 38: 3049–51PubMedCrossRefGoogle Scholar
  81. 81.
    Chen Y, Guo JJ, Patel NC. Hemorrhagic stroke associated with antidepressant use in patients with depression: does degree of serotonin reuptake inhibition matter? Pharmacoepidemiol Drug Saf 2009; 18: 196–202PubMedCrossRefGoogle Scholar
  82. 82.
    Smoller JW, Allison M, Cochrane BB, et al. Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the Women’s Health Initiative study. Arch Intern Med 2009; 169: 2128–39PubMedCrossRefGoogle Scholar
  83. 83.
    Kurdyak PA, Juurlink DN, Kopp A, et al. Antidepressants, warfarin, and the risk of hemorrhage. J Clin Psychopharmacol 2005 Dec; 25(6): 561–4PubMedCrossRefGoogle Scholar
  84. 84.
    Schalekamp T, Klungel OH, Souverein PC, et al. Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Arch Intern Med 2008; 168: 180–5PubMedCrossRefGoogle Scholar
  85. 85.
    Wallerstedt SM, Gleerup H, Sundström A, et al. Risk of clinically relevant bleeding in warfarin-treated patients: influence of SSRI treatment. Pharmacoepidemiol Drug Saf 2009; 18:412–6PubMedCrossRefGoogle Scholar
  86. 86.
    Hauta-Aho M, Tirkkonen T, Vahlberg T, et al. The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients. Ann Med 2009; 41: 619–28PubMedCrossRefGoogle Scholar
  87. 87.
    Layton D, Clark DWJ, Pearce GL, et al. Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England. Eur J Clin Pharmacol 2001; 57: 167–76PubMedCrossRefGoogle Scholar
  88. 88.
    Meijer WE, Heerdink ER, Nolen WA, et al. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med 2004; 164: 2367–70PubMedCrossRefGoogle Scholar
  89. 89.
    Ziegelstein RC, Meuchel J, Kim TJ, et al. Selective serotonin reuptake inhibitor use by patients with acute coronary syndromes. Am J Med 2007; 120: 525–30PubMedCrossRefGoogle Scholar
  90. 90.
    Dentali F, Douketis JD, Lim W, et al. Combined aspirin: oral anticoagulant therapy compared with oral anti-coagulant therapy alone among patients at risk for cardiovascular disease — a meta-analysis of randomized trials. Arch Intern Med 2007; 167: 117–24PubMedCrossRefGoogle Scholar
  91. 91.
    Delaney JA, Opatrny L, Brophy JM, et al. Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 2007; 177: 347–51PubMedCrossRefGoogle Scholar
  92. 92.
    Wulsin LR, Singal BM. Do depressive symptoms increase the risk for the onset of coronary disease? A systematic quantitative review. Psychosom Med 2003; 65: 201–10PubMedCrossRefGoogle Scholar
  93. 93.
    Glassman AH. Depression and cardiovascular comorbidity. Dialogues Clin Neurosci 2007; 9: 9–17PubMedGoogle Scholar
  94. 94.
    Salaycik KJ, Kelly-Hayes M, Beiser A, et al. Depressive symptoms and risk of stroke: the Framingham Study. Stroke 2007; 38: 16–21PubMedCrossRefGoogle Scholar
  95. 95.
    O’Donnell MJ, Xavier D, Liu L, et al., INTERSTROKE investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010; 376: 112–23PubMedCrossRefGoogle Scholar
  96. 96.
    Bonnet F, Irving K, Terra JL, et al. Anxiety and depression are associated with unhealthy lifestyle in patients at risk of cardiovascular disease. Atherosclerosis 2005; 178: 339–44PubMedCrossRefGoogle Scholar
  97. 97.
    Bruce EC, Musselman DL. Depression, alterations in platelet function, and ischemic heart disease. Psychosom Med 2005; 67Suppl. 1: S34–6PubMedCrossRefGoogle Scholar
  98. 98.
    Brown AD, Barton DA, Lambert GW. Cardiovascular abnormalities in patients with major depressive disorder autonomic mechanisms and implications for treatment. CNS Drugs 2009; 23: 583–602PubMedCrossRefGoogle Scholar
  99. 99.
    Vaccarino V, Johnson BD, Sheps DS, et al. Depression, inflammation, and incident cardiovascular disease in women with suspected coronary ischemia: the National Heart, Lung, and Blood Institute-sponsored WISE study. J Am Coll Cardiol 2007; 50: 2044–50PubMedCrossRefGoogle Scholar
  100. 100.
    Leo R, Di Lorenzo G, Tesauro M, et al. Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy. J Clin Psychiatry 2006; 67: 1760–6PubMedCrossRefGoogle Scholar
  101. 101.
    Lekakis J, Ikonomidis I, Papoutsi Z, et al. Selective serotonin re-uptake inhibitors decrease the cytokine-induced endothelial adhesion molecule expression, the endothelial adhesiveness to monocytes and the circulating levels of vascular adhesion molecules. Int J Cardiol 2010; 139: 150–8PubMedCrossRefGoogle Scholar
  102. 102.
    Sher Y, Lolak S, Maldonado JR. The impact of depression in heart disease. Curr Psychiatry Rep 2010; 12: 255–64PubMedCrossRefGoogle Scholar
  103. 103.
    MacDonald TM, McMahon AD, Reid IC, et al. Antide-pressant drug use in primary care: a record linkage study in Tayside, Scotland. BMJ 1996; 313: 860–1PubMedCrossRefGoogle Scholar
  104. 104.
    Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antide-pressant medications: association with use of tricyclic agents. Am J Med 2000; 108: 2–8PubMedCrossRefGoogle Scholar
  105. 105.
    Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 2001; 104: 1894–8PubMedCrossRefGoogle Scholar
  106. 106.
    Meier CR, Schlienger RG, Jick H. Use of selective serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction. Br J Clin Pharmacol 2001; 52: 179–84PubMedCrossRefGoogle Scholar
  107. 107.
    Hippisley-Cox J, Pringle M, Hammersley V, et al. Antide-pressants as risk factor for ischaemic heart disease: case-control study in primary care. BMJ 2001; 323: 666–9PubMedCrossRefGoogle Scholar
  108. 108.
    Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation 2003; 108: 32–6PubMedCrossRefGoogle Scholar
  109. 109.
    Schlienger RG, Fischer LM, Jick H, et al. Current use of selective serotonin reuptake inhibitors and risk of acute myocardial infarction. Drug Saf 2004; 27: 1157–65PubMedCrossRefGoogle Scholar
  110. 110.
    Monster TB, Johnsen SP, Olsen ML, et al. Antidepressants and risk of first-time hospitalization for myocardial infarction: a population-based case-control study. Am J Med 2004 Nov 15; 117(10): 732–7PubMedCrossRefGoogle Scholar
  111. 111.
    Tata LJ, West J, Smith C, et al. General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. Heart 2005; 91: 465–71PubMedCrossRefGoogle Scholar
  112. 112.
    Barbui C, Percudani M, Fortino I, et al. Past use of selective serotonin reuptake inhibitors and the risk of cerebrovascular events in the elderly. Int Clin Psychopharmacol 2005; 20: 169–71PubMedCrossRefGoogle Scholar
  113. 113.
    Chen Y, Guo JJ, Li H, et al. Risk of cerebrovascular events associated with antidepressant use in patients with depression: a population-based, nested case-control study. Ann Pharmacother 2008; 42: 177–84PubMedCrossRefGoogle Scholar
  114. 114.
    Trifiro G, Dieleman J, Sen EF, et al. Risk of ischemic stroke associated with antidepressant drug use in elderly persons. J Clin Psychopharmacol 2010; 30: 252–8PubMedCrossRefGoogle Scholar
  115. 115.
    Tiihonen J, Lonnqvist J, Wahlbeck K, et al. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry 2006; 63: 1358–67PubMedCrossRefGoogle Scholar
  116. 116.
    Rudisch B, Nemeroff CB. Epidemiology of comorbid coronary artery disease and depression. Biol Psychiatry 2003; 54: 227–40PubMedCrossRefGoogle Scholar
  117. 117.
    Carney RM, Rich MW, Freedland KE, et al. Major depressive disorder predicts cardiac events in patients with coronary artery disease. Psychosom Med 1988; 50: 627–33PubMedGoogle Scholar
  118. 118.
    Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med 2004; 66: 802–13PubMedCrossRefGoogle Scholar
  119. 119.
    van Melle JP, de Jonge P, Spijkerman TA, et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med 2004; 66: 814–22PubMedCrossRefGoogle Scholar
  120. 120.
    Lesperance F, Frasure-Smith N, Talajic M, et al. Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. Circulation 2002; 105: 1049–53PubMedCrossRefGoogle Scholar
  121. 121.
    Bush DE, Ziegelstein RC, Tayback M, et al. Even minimal symptoms of depression increase mortality risk after acute myocardial infarction. Am J Cardiol 2001; 88: 337–41PubMedCrossRefGoogle Scholar
  122. 122.
    De Jonge P, Honig A, van Melle JP, et al., MIND-IT Investigators. Nonresponse to treatment for depression following myocardial infarction: association with subsequent cardiac events. Am J Psychiatry 2007; 164: 1371–8PubMedCrossRefGoogle Scholar
  123. 123.
    Whooley MA. Depression and cardiovascular disease: healing the broken-hearted. JAMA 2006; 295: 2874–81PubMedCrossRefGoogle Scholar
  124. 124.
    Whooley MA, de Jonge P, Vittinghoff E, et al. Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA 2008; 300: 2379–88PubMedCrossRefGoogle Scholar
  125. 125.
    Huffman JC, Celano CM, Januzzi JL. The relationship between depression, anxiety, and cardiovascular outcomes in patients with acute coronary syndromes. Neuropsychiatr Dis Treat 2010; 6: 123–36PubMedCrossRefGoogle Scholar
  126. 126.
    Brondy B. Common genetic factors for depression and cardiovascular disease. Dialogues Clin Neurosci 2007; 9: 19–28Google Scholar
  127. 127.
    Robinson RG. Poststroke depression: prevalence, diagnosis, treatment, and disease progression. Biol Psychiatry 2003; 54: 376–87PubMedCrossRefGoogle Scholar
  128. 128.
    Ohira T, Iso H, Satoh S, et al. Prospective study of depressive symptoms and risk of stroke among Japanese. Stroke 2001; 32: 903–8PubMedCrossRefGoogle Scholar
  129. 129.
    Lyketsos CG, Treisman GJ, Lipsey JR, et al. Does stroke cause depression? J Neuropsychiatry Clin Neurosci 1998; 10: 103–7PubMedGoogle Scholar
  130. 130.
    Carney RM, Freeland KE. Depression and coronary heart disease: more pieces of the puzzle. Am J Psychiatry 2007; 164: 1307–9PubMedCrossRefGoogle Scholar
  131. 131.
    Carney RM, Freeland KE. Does treating depression improve survival after acute coronary syndrome? Br J Psychiatry 2007; 190: 467–8PubMedCrossRefGoogle Scholar
  132. 132.
    Glassman AH, O’Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002; 288: 701–9PubMedCrossRefGoogle Scholar
  133. 133.
    Berkman LF, Blumenthal J, Burg M, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA 2003; 289: 3106–16PubMedCrossRefGoogle Scholar
  134. 134.
    Taylor CB, Youngblood ME, Catellier D, et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 2005; 62: 792–8PubMedCrossRefGoogle Scholar
  135. 135.
    van Melle JP, de Jonge P, Honig A, et al. Effects of anti-depressant treatment following myocardial infarction. Br J Psychiatry 2007; 190: 460–6PubMedCrossRefGoogle Scholar
  136. 136.
    Lesperance F, Frasure-Smith N, Koszycki D, et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA 2007; 297: 367–79PubMedCrossRefGoogle Scholar
  137. 137.
    Hansen BH, Hanash JA, Rasmussen A, et al. Rationale, design and methodology of a double-blind, randomized, placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD). Trials 2009; 10: 20PubMedCrossRefGoogle Scholar
  138. 138.
    Rasmussen A, Lunde M, Poulsen DL, et al. A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients. Psychosomatics 2003; 44: 216–21PubMedCrossRefGoogle Scholar
  139. 139.
    Robinson RG, Jorge RE, Moser DJ, et al. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. JAMA 2008; 299: 2391–400PubMedCrossRefGoogle Scholar
  140. 140.
    Croom KF, Perry CM, Plosker GL. Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs 2009; 23: 427–52PubMedCrossRefGoogle Scholar
  141. 141.
    Swenson JR, Doucette S, Fergusson D. Adverse cardiovascular events in antidepressant trials involving high-risk patients: a systematic review of randomized trials. Can J Psychiatry 2006; 51: 923–9PubMedGoogle Scholar
  142. 142.
    Mazza M, Lotrionte M, Biondi-Zoccai G, et al. Selective serotonin reuptake inhibitors provide significant lower rehospitalization rates in patients recovering from acute coronary syndromes: evidence from a meta-analysis. J Psychopharmacol 2010; 24: 1785–92PubMedCrossRefGoogle Scholar
  143. 143.
    Serebruany VL, Glassman AH, Malinin AI, et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 2003; 108: 939–44PubMedCrossRefGoogle Scholar
  144. 144.
    Krantz DS, Whittaker KS, Francis JL, et al. Psychotropic medication use and risk of adverse cardiovascular events in women with suspected coronary artery disease: outcomes from the Women’s Ischemia Syndrome Evaluation (WISE) study. Heart 2009; 95: 1901–6PubMedCrossRefGoogle Scholar
  145. 145.
    Massó González EL, Patrignani P, Tacconelli S, et al. Variability among nonsteroidal anti-inflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum 2010; 62: 1592–601PubMedCrossRefGoogle Scholar
  146. 146.
    Lichtman JH, Bigger JT, Blumenthal JA, et al. Depression and coronary heart disease: recommendations for screening referral, and treatment. A Science Advisory From the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: Endorsed by the American Psychiatric Association. Circulation 2008; 118: 1768–75PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  • Francisco J. de Abajo
    • 1
    • 2
  1. 1.Clinical Pharmacology UnitHospital Universitario “Príncipe de Asturias”MadridSpain
  2. 2.Department of Pharmacology, School of MedicineUniversity of AlcaláMadridSpain

Personalised recommendations